Bright Research Development from 2010 to 2026

DRUG Stock  USD 90.00  0.91  1.02%   
Bright Minds' Research Development is increasing over the last several years with slightly volatile swings. Research Development is estimated to finish at about 13.4 M this year. During the period from 2010 to 2026 Bright Minds Biosciences Research Development regressed destribution of quarterly values had coefficient of variationof  141.15 and r-value of  0.78. View All Fundamentals
 
Research Development  
First Reported
2019-12-31
Previous Quarter
4.8 M
Current Value
5.7 M
Quarterly Volatility
1.5 M
 
Covid
 
Interest Hikes
Check Bright Minds financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bright Minds' main balance sheet or income statement drivers, such as Depreciation And Amortization of 54.2 K, Interest Expense of 49.2 K or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.73. Bright financial statements analysis is a perfect complement when working with Bright Minds Valuation or Volatility modules.
  
Build AI portfolio with Bright Stock
Check out the analysis of Bright Minds Correlation against competitors.
The Research Development trend for Bright Minds Biosciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bright Minds is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Bright Minds' Research Development Growth Pattern

Below is the plot of the Research Development of Bright Minds Biosciences over the last few years. It is Bright Minds' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Bright Research Development Regression Statistics

Arithmetic Mean3,728,248
Geometric Mean702,006
Coefficient Of Variation141.15
Mean Deviation4,510,779
Median126,027
Standard Deviation5,262,535
Sample Variance27.7T
Range13.3M
R-Value0.78
Mean Square Error11.3T
R-Squared0.62
Significance0.0002
Slope817,898
Total Sum of Squares443.1T

Bright Research Development History

202613.4 M
202512.7 M
202411.1 M
20231.2 M
2022M
202112.2 M
20206.3 M

About Bright Minds Financial Statements

Bright Minds stakeholders use historical fundamental indicators, such as Bright Minds' Research Development, to determine how well the company is positioned to perform in the future. Although Bright Minds investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bright Minds' assets and liabilities are reflected in the revenues and expenses on Bright Minds' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bright Minds Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development12.7 M13.4 M

Currently Active Assets on Macroaxis

When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Check out the analysis of Bright Minds Correlation against competitors.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Can Biotechnology industry sustain growth momentum? Does Bright have expansion opportunities? Factors like these will boost the valuation of Bright Minds. Projected growth potential of Bright fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bright Minds demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(2.02)
Return On Assets
(0.16)
Return On Equity
(0.27)
Bright Minds Biosciences's market price often diverges from its book value, the accounting figure shown on Bright's balance sheet. Smart investors calculate Bright Minds' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Bright Minds' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bright Minds' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bright Minds should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.